Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation-Reference-Cited by-同舟云学术

Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation

Published:2021-01-26 Issue:1 Volume:15 Page:137-145
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Lee Soon Kyu,Jang Jeong Won,Nam Heechul,Sung Pil Soo,Kim Hee Yeon,Kwon Jung Hyun,Lee Sung Won,Song Do Seon,Kim Chang Wook,Song Myeong Jun,Choi Ho Joong,You Young Kyoung,Bae Si Hyun,Choi Jong Young,Yoon Seung Kew

Funder

National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-020-10131-0.pdf

Reference30 articles.

1. Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430–46.

2. Keating GM. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 2017;12:243–53.

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

4. Branco F, Alencar RS, Volt F, Sartori G, Dode A, Kikuchi L, et al. The impact of early dermatologic events in the survival of patients with hepatocellular carcinoma treated with sorafenib. Ann Hepatol. 2017;16:263–8.

5. Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, et al. Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events. Hepatology. 2018;67:612–22.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequential regorafenib or nivolumab therapy in recurrent hepatocellular carcinoma with sorafenib failure in liver transplant patients does not improve prognosis;Annals of Liver Transplantation;2023-11-30

2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma;Biochemical Genetics;2023-10-29

3. Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?;Journal of Hepatology;2023-10

4. Recent advances in recurrent hepatocellular carcinoma therapy;World Journal of Hepatology;2023-04-27

5. The Role of Ferroptosis and Cuproptosis in Curcumin against Hepatocellular Carcinoma;Molecules;2023-02-08